Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ ELECTROPHYSIOLOGY — Sales to Customers

Other product segments

DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Boston Scientific logo
BSXElectrophysiology — Net Sales
$905M+24.0%
Lantheus Holdings logo
LNTHCardiology — Revenue
$84.63M+6.8%
Boston Scientific logo
BSXCardiac Rhythm Management — Net Sales
$578M0.0%
CeriBell, Inc. logo
CBLLEEG Recorders And Wearables Sales Point In Time — Revenue
$20.19M+29.4%
Utah Medical Products logo
UTMDGynecology Electrosurgery Urology — Revenue
$5.23M+6.8%
ITG
ITGRCardiac Rhythm Management & Neuromodulation — Total sales
$168.26M+4.9%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-K, filed February 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's electrophysiology — sales to customers.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's ELECTROPHYSIOLOGY — sales to customers?
Johnson & Johnson (JNJ) reported ELECTROPHYSIOLOGY — sales to customers of $1.41B in Q4 2025.
How has Johnson & Johnson's ELECTROPHYSIOLOGY — sales to customers changed year-over-year?
Johnson & Johnson's ELECTROPHYSIOLOGY — sales to customers increased by 7.0% year-over-year, from $1.32B to $1.41B.
What is the long-term trend for Johnson & Johnson's ELECTROPHYSIOLOGY — sales to customers?
Over 4 years (2021 to 2025), Johnson & Johnson's ELECTROPHYSIOLOGY — sales to customers has grown at a 11.7% compound annual growth rate (CAGR), from $3.62B to $5.63B.
What does ELECTROPHYSIOLOGY — sales to customers mean?
This metric represents the total revenue generated from the sale of electrophysiology medical devices and related technologies to external customers. It serves as a key indicator of the market adoption and commercial performance of the company's cardiac rhythm management and diagnostic product portfolio. Tracking this revenue stream helps investors assess the company's competitive position in the specialized cardiovascular medical device market.